

# Contents

|                                                                   |    |                                                                              |    |
|-------------------------------------------------------------------|----|------------------------------------------------------------------------------|----|
| <b>1 Low-Grade Gliomas</b><br>Gregory Gan • Daphne Haas-Kogan     |    | <b>2.4 Clinical Features</b> . . . . .                                       | 39 |
| <b>1.1 Introduction</b> . . . . .                                 | 2  | <b>2.5 Diagnostic Imaging</b> . . . . .                                      | 39 |
| <b>1.2 Astrocytomas</b> . . . . .                                 | 2  | <b>2.6 Treatment</b> . . . . .                                               | 42 |
| 1.2.1 Epidemiology . . . . .                                      | 2  | 2.6.1 Surgery . . . . .                                                      | 42 |
| 1.2.2 Pathology . . . . .                                         | 3  | 2.6.2 Radiation Therapy . . . . .                                            | 43 |
| 1.2.3 Clinical Features . . . . .                                 | 6  | 2.6.3 Chemotherapy . . . . .                                                 | 44 |
| 1.2.4 Diagnostic Imaging . . . . .                                | 6  | <b>2.7 Outcome</b> . . . . .                                                 | 44 |
| 1.2.5 Treatment . . . . .                                         | 8  | <b>2.8 Future Directions</b> . . . . .                                       | 45 |
| 1.2.6 Outcome . . . . .                                           | 11 | <b>2.9 Conclusions</b> . . . . .                                             | 46 |
| <b>1.3 Cerebellar Astrocytoma</b> . . . . .                       | 12 | <b>References</b> . . . . .                                                  | 46 |
| 1.3.1 Epidemiology . . . . .                                      | 12 |                                                                              |    |
| 1.3.2 Pathology . . . . .                                         | 12 | <b>3 Brainstem Gliomas</b><br>Nader Sanai • Michael Prados                   |    |
| 1.3.3 Clinical Features . . . . .                                 | 13 | <b>3.1 Introduction</b> . . . . .                                            | 49 |
| 1.3.4 Natural History . . . . .                                   | 14 | <b>3.2 Epidemiology</b> . . . . .                                            | 50 |
| 1.3.5 Diagnosis and Neuroimaging . . . . .                        | 14 | <b>3.3 Pathology</b> . . . . .                                               | 51 |
| 1.3.6 Treatment . . . . .                                         | 15 | 3.3.1 Histopathology . . . . .                                               | 51 |
| 1.3.7 Outcome . . . . .                                           | 18 | 3.3.2 Molecular Biology . . . . .                                            | 51 |
| 1.3.8 Conclusion . . . . .                                        | 20 | <b>3.4 Clinical Features</b> . . . . .                                       | 52 |
| <b>1.4 Optic Pathway Gliomas</b> . . . . .                        | 20 | 3.4.1 Growth Pattern . . . . .                                               | 52 |
| 1.4.1 Epidemiology . . . . .                                      | 21 | 3.4.2 Prognostic Factors . . . . .                                           | 54 |
| 1.4.2 Pathology . . . . .                                         | 21 | <b>3.5 Diagnosis and Imaging</b> . . . . .                                   | 54 |
| 1.4.3 Clinical Features . . . . .                                 | 21 | 3.5.1 Computed Tomography and<br>Magnetic Resonance Imaging . . . . .        | 54 |
| 1.4.4 Diagnostic Imaging . . . . .                                | 22 | 3.5.2 Role of Diagnostic Biopsy for<br>Diffuse Pontine Glioma . . . . .      | 57 |
| 1.4.5 Treatment . . . . .                                         | 22 | <b>3.6 Treatment</b> . . . . .                                               | 59 |
| 1.4.6 Outcome . . . . .                                           | 25 | 3.6.1 Radiotherapy . . . . .                                                 | 59 |
| <b>1.5 Oligodendroglioma</b> . . . . .                            | 26 | 3.6.2 Chemotherapy for Diffuse<br>Pontine Glioma . . . . .                   | 60 |
| 1.5.1 Epidemiology . . . . .                                      | 26 | 3.6.3 Surgery and Adjunctive<br>Treatment for Nondiffuse<br>Tumors . . . . . | 61 |
| 1.5.2 Pathology . . . . .                                         | 27 | <b>3.7 Conclusion</b> . . . . .                                              | 62 |
| 1.5.3 Clinical Features . . . . .                                 | 27 | <b>References</b> . . . . .                                                  | 62 |
| 1.5.4 Diagnostic Imaging . . . . .                                | 27 |                                                                              |    |
| 1.5.5 Treatment . . . . .                                         | 27 |                                                                              |    |
| 1.5.6 Outcome . . . . .                                           | 28 |                                                                              |    |
| <b>1.6 Conclusion</b> . . . . .                                   | 28 |                                                                              |    |
| <b>References</b> . . . . .                                       | 28 |                                                                              |    |
| <b>2 High-Grade Gliomas</b><br>Sabine Mueller • Daphne Haas-Kogan |    | <b>4 Ependymoma</b><br>Matthew D. Smyth • Joshua Rubin                       |    |
| <b>2.1 Introduction</b> . . . . .                                 | 37 | <b>4.1 Epidemiology</b> . . . . .                                            | 67 |
| <b>2.2 Epidemiology</b> . . . . .                                 | 37 | 4.1.1 Incidence . . . . .                                                    | 67 |
| <b>2.3 Pathology</b> . . . . .                                    | 38 | 4.1.2 Age and Sex Distribution . . . . .                                     | 67 |
| 2.3.1 Histopathology . . . . .                                    | 38 |                                                                              |    |
| 2.3.2 Molecular Biology . . . . .                                 | 38 |                                                                              |    |

|                   |                                         |    |
|-------------------|-----------------------------------------|----|
| 4.1.3             | Environmental and Viral Causes          | 68 |
| 4.1.4             | Genetic Predisposition                  | 68 |
| <b>4.2</b>        | <b>Pathology</b>                        | 68 |
| 4.2.1             | Histopathology                          | 68 |
| 4.2.2             | Genetics and Molecular Biology          | 71 |
| <b>4.3</b>        | <b>Clinical Features</b>                | 73 |
| <b>4.4</b>        | <b>Natural History and Risk Factors</b> | 73 |
| <b>4.5</b>        | <b>Diagnosis</b>                        | 74 |
| <b>4.6</b>        | <b>Treatment</b>                        | 74 |
| 4.6.1             | Surgery                                 | 74 |
| 4.6.2             | Radiation Therapy                       | 76 |
| 4.6.3             | Chemotherapy                            | 78 |
| 4.6.4             | Spinal Cord Ependymomas                 | 80 |
| 4.6.5             | Recurrent Disease                       | 81 |
| <b>4.7</b>        | <b>Outcome</b>                          | 81 |
| 4.7.1             | Neurologic Function                     | 81 |
| 4.7.2             | Progression-Free Survival               | 82 |
| <b>4.8</b>        | <b>Conclusions</b>                      | 83 |
| <b>References</b> |                                         | 83 |

## 5 Embryonal Tumors

Sonia Partap • Paul Graham Fisher

|                   |                                         |     |
|-------------------|-----------------------------------------|-----|
| <b>5.1</b>        | <b>Introduction</b>                     | 89  |
| <b>5.2</b>        | <b>Medulloblastoma</b>                  | 90  |
| 5.2.1             | Epidemiology                            | 90  |
| 5.2.2             | Pathology                               | 90  |
| 5.2.3             | Clinical Features                       | 96  |
| 5.2.4             | Natural History                         | 96  |
| 5.2.5             | Diagnostic Imaging                      | 96  |
| 5.2.6             | Treatment                               | 97  |
| 5.2.7             | Outcome                                 | 102 |
| 5.2.8             | Future Directions                       | 104 |
| <b>5.3</b>        | <b>Atypical Teratoid/Rhabdoid Tumor</b> | 105 |
| 5.3.1             | Epidemiology                            | 105 |
| 5.3.2             | Pathology                               | 105 |
| 5.3.3             | Treatment                               | 105 |
| <b>5.4</b>        | <b>Other Embryonal Tumors</b>           | 106 |
| 5.4.1             | Pineoblastoma                           | 106 |
| 5.4.2             | Other Nonpineal Embryonal Tumors        | 107 |
| <b>5.5</b>        | <b>Conclusions</b>                      | 108 |
| <b>References</b> |                                         | 108 |

## 6 Intracranial Germ-Cell Tumors

Sean M. McBride • Daphne Haas-Kogan

|            |                                    |     |
|------------|------------------------------------|-----|
| <b>6.1</b> | <b>Introduction</b>                | 115 |
| <b>6.2</b> | <b>Epidemiology</b>                | 116 |
| 6.2.1      | Location                           | 116 |
| 6.2.2      | Age, Sex, and Geographic Variation | 116 |

|                   |                                              |     |
|-------------------|----------------------------------------------|-----|
| <b>6.3</b>        | <b>Pathology</b>                             | 117 |
| 6.3.1             | Etiology                                     | 117 |
| 6.3.2             | Classification                               | 117 |
| 6.3.3             | Histopathology                               | 118 |
| 6.3.4             | Molecular Biology and Cytogenetics           | 118 |
| <b>6.4</b>        | <b>Clinical Features: Signs and Symptoms</b> | 119 |
| <b>6.5</b>        | <b>Diagnosis and Staging</b>                 | 119 |
| 6.5.1             | Laboratory Investigations                    | 119 |
| 6.5.2             | Diagnostic Imaging                           | 120 |
| 6.5.3             | Obtaining Tissue Diagnosis                   | 121 |
| <b>6.6</b>        | <b>Treatment</b>                             | 123 |
| 6.6.1             | Role of Surgery                              | 123 |
| 6.6.2             | Chemotherapy                                 | 124 |
| 6.6.3             | Radiation Therapy                            | 125 |
| 6.6.4             | Combined Modality Treatment                  | 126 |
| 6.6.5             | Treatment of Recurrent Disease               | 128 |
| 6.6.6             | Future Trials                                | 128 |
| <b>6.7</b>        | <b>Outcome</b>                               | 129 |
| <b>6.8</b>        | <b>Conclusions</b>                           | 130 |
| <b>References</b> |                                              | 130 |

## 7 Craniopharyngioma

Michael E. Sughrue •

Robert H. Lustig • Benjamin Fisch •

Michael W. McDermott

|                   |                                                       |     |
|-------------------|-------------------------------------------------------|-----|
| <b>7.1</b>        | <b>Introduction</b>                                   | 135 |
| <b>7.2</b>        | <b>Epidemiology</b>                                   | 135 |
| <b>7.3</b>        | <b>Pathology</b>                                      | 136 |
| 7.3.1             | Etiology                                              | 136 |
| 7.3.2             | Classification                                        | 136 |
| 7.3.3             | Histopathology                                        | 136 |
| 7.3.4             | Tumor Biology                                         | 137 |
| <b>7.4</b>        | <b>Clinical Features</b>                              | 138 |
| 7.4.1             | Neurologic Signs and Symptoms                         | 138 |
| 7.4.2             | Endocrine Signs and Symptoms                          | 139 |
| <b>7.5</b>        | <b>Natural History</b>                                | 139 |
| <b>7.6</b>        | <b>Diagnosis and Imaging</b>                          | 140 |
| 7.6.1             | Computed Tomography<br>and Magnetic Resonance Imaging | 140 |
| 7.6.2             | Clinical Evaluation                                   | 141 |
| <b>7.7</b>        | <b>Treatment</b>                                      | 142 |
| 7.7.1             | Surgery                                               | 143 |
| 7.7.2             | Radiotherapy                                          | 145 |
| 7.7.3             | Chemotherapy                                          | 148 |
| <b>7.8</b>        | <b>Outcome</b>                                        | 148 |
| <b>7.9</b>        | <b>Complications Associated with Treatment</b>        | 150 |
| 7.9.1             | Complications of Surgery                              | 150 |
| 7.9.2             | Complications of Radiotherapy                         | 151 |
| 7.9.3             | Complications of Radiosurgery                         | 152 |
| 7.9.4             | Hypothalamic Injury                                   | 153 |
| <b>7.10</b>       | <b>Conclusions</b>                                    | 154 |
| <b>References</b> |                                                       | 154 |

**8 Neuronal Tumors**

Edward F. Chang • Nalin Gupta

|                                                   |     |
|---------------------------------------------------|-----|
| <b>8.1 Ganglioglioma and Gangliocytoma</b>        | 160 |
| 8.1.1 Epidemiology                                | 160 |
| 8.1.2 Pathology                                   | 160 |
| 8.1.3 Clinical Features                           | 161 |
| 8.1.4 Natural History                             | 162 |
| 8.1.5 Diagnosis and Neuroimaging                  | 162 |
| 8.1.6 Treatment                                   | 162 |
| 8.1.7 Outcome                                     | 163 |
| <b>8.2 Dysembryoplastic Neuroepithelial Tumor</b> | 163 |
| 8.2.1 Epidemiology                                | 163 |
| 8.2.2 Pathology                                   | 163 |
| 8.2.3 Clinical Features                           | 165 |
| 8.2.4 Natural History                             | 165 |
| 8.2.5 Diagnosis and Neuroimaging                  | 165 |
| 8.2.6 Treatment                                   | 165 |
| 8.2.7 Outcome                                     | 165 |
| <b>8.3 Central Neurocytoma</b>                    | 166 |
| 8.3.1 Epidemiology                                | 166 |
| 8.3.2 Pathology                                   | 166 |
| 8.3.3 Clinical Features                           | 167 |
| 8.3.4 Natural History                             | 167 |
| 8.3.5 Diagnosis and Neuroimaging                  | 167 |
| 8.3.6 Treatment                                   | 168 |
| 8.3.7 Outcome                                     | 169 |
| <b>8.4 Conclusions</b>                            | 169 |
| <b>References</b>                                 | 170 |

**9 Choroid Plexus Tumors**

Nalin Gupta

|                                                 |     |
|-------------------------------------------------|-----|
| <b>9.1 Introduction</b>                         | 175 |
| <b>9.2 Epidemiology</b>                         | 175 |
| <b>9.3 Pathology</b>                            | 176 |
| 9.3.1 Gross Appearance                          | 176 |
| 9.3.2 Histopathology                            | 176 |
| 9.3.3 Immunohistochemistry                      | 177 |
| 9.3.4 Genetics                                  | 177 |
| <b>9.4 Clinical Features</b>                    | 178 |
| <b>9.5 Diagnosis and Neuroimaging</b>           | 178 |
| 9.5.1 Computed Tomography                       | 178 |
| 9.5.2 Magnetic Resonance Imaging                | 179 |
| <b>9.6 Treatment</b>                            | 179 |
| 9.6.1 Preoperative Planning                     | 179 |
| 9.6.2 Operative Treatment                       | 180 |
| 9.6.3 Treatment of Choroid Plexus<br>Carcinomas | 181 |
| <b>9.7 Outcome</b>                              | 182 |
| <b>9.8 Conclusions</b>                          | 183 |
| <b>References</b>                               | 183 |

**10 Intramedullary Spinal Cord Tumors**

Isaac Yang • Andrew T. Parsa

|                                                                       |     |
|-----------------------------------------------------------------------|-----|
| <b>10.1 Introduction</b>                                              | 187 |
| <b>10.2 Ependymoma</b>                                                | 188 |
| 10.2.1 Epidemiology                                                   | 188 |
| 10.2.2 Pathology                                                      | 188 |
| 10.2.3 Clinical Features                                              | 190 |
| 10.2.4 Diagnostic Imaging                                             | 191 |
| <b>10.3 Astrocytoma</b>                                               | 192 |
| 10.3.1 Epidemiology                                                   | 192 |
| 10.3.2 Pathology                                                      | 193 |
| 10.3.3 Clinical Features                                              | 194 |
| 10.3.4 Diagnostic Imaging                                             | 194 |
| <b>10.4 Von Hippel–Lindau Disease<br/>and Spinal Hemangioblastoma</b> | 194 |
| <b>10.5 Other Intramedullary Spinal<br/>Cord Tumors and Lesions</b>   | 196 |
| <b>10.6 Treatment</b>                                                 | 196 |
| 10.6.1 Surgery                                                        | 196 |
| 10.6.2 Radiation                                                      | 198 |
| 10.6.3 Chemotherapy                                                   | 198 |
| <b>10.7 Outcome</b>                                                   | 199 |
| 10.7.1 Disease Control                                                | 199 |
| 10.7.2 Functional Outcome                                             | 199 |
| <b>10.8 Conclusions</b>                                               | 200 |
| <b>References</b>                                                     | 200 |

**11 Rare Tumors**

Sunanda Pejaver • Daphne Haas-Kogan

|                                                         |     |
|---------------------------------------------------------|-----|
| <b>11.1 Meningioma</b>                                  | 205 |
| 11.1.1 Epidemiology                                     | 205 |
| 11.1.2 Histopathology                                   | 206 |
| 11.1.3 Clinical Features                                | 206 |
| 11.1.4 Diagnosis and Neuroimaging                       | 206 |
| 11.1.5 Treatment                                        | 207 |
| 11.1.6 Outcome                                          | 208 |
| <b>11.2 Pediatric Pituitary Adenoma</b>                 | 208 |
| 11.2.1 Epidemiology                                     | 208 |
| 11.2.2 Histopathology                                   | 209 |
| 11.2.3 Clinical Features                                | 209 |
| 11.2.4 Diagnosis and Neuroimaging                       | 210 |
| 11.2.5 Treatment                                        | 211 |
| 11.2.6 Outcome                                          | 213 |
| <b>11.3 Primary Central Nervous<br/>System Lymphoma</b> | 214 |
| 11.3.1 Epidemiology                                     | 214 |
| 11.3.2 Histopathology                                   | 214 |
| 11.3.3 Clinical Features                                | 214 |
| 11.3.4 Diagnosis and Neuroimaging                       | 215 |
| 11.3.5 Treatment                                        | 215 |
| 11.3.6 Outcome                                          | 216 |

|                                             |     |
|---------------------------------------------|-----|
| <b>11.4 Hemangioblastoma</b> . . . . .      | 217 |
| 11.4.1 Epidemiology . . . . .               | 217 |
| 11.4.2 Histopathology . . . . .             | 217 |
| 11.4.3 Clinical Features . . . . .          | 217 |
| 11.4.4 Diagnosis and Neuroimaging . . . . . | 217 |
| 11.4.5 Treatment . . . . .                  | 218 |
| <b>11.5 Conclusions</b> . . . . .           | 219 |
| <b>References</b> . . . . .                 | 219 |

## **12 Neurocutaneous Syndromes and Associated CNS Tumors**

Sabine Mueller • Daphne Haas-Kogan

|                                                            |     |
|------------------------------------------------------------|-----|
| <b>12.1 Introduction</b> . . . . .                         | 224 |
| <b>12.2 Neurofibromatosis Type 1</b> . . . . .             | 224 |
| 12.2.1 Epidemiology . . . . .                              | 224 |
| 12.2.2 Diagnostic Criteria and Clinical Features . . . . . | 225 |
| 12.2.3 Natural History and Prognosis . . . . .             | 226 |
| 12.2.4 Laboratory Studies . . . . .                        | 226 |
| 12.2.5 Imaging Studies . . . . .                           | 227 |
| 12.2.6 Treatment . . . . .                                 | 227 |
| <b>12.3 Neurofibromatosis Type 2</b> . . . . .             | 228 |
| 12.3.1 Epidemiology . . . . .                              | 228 |
| 12.3.2 Molecular Biology and Cytogenetics . . . . .        | 229 |
| 12.3.3 Diagnostic Criteria and Clinical Features . . . . . | 229 |
| 12.3.4 Natural History and Prognosis . . . . .             | 230 |
| 12.3.5 Laboratory Studies . . . . .                        | 230 |
| 12.3.6 Imaging Studies . . . . .                           | 230 |
| 12.3.7 Treatment . . . . .                                 | 231 |
| <b>12.4 Tuberous Sclerosis Complex</b> . . . . .           | 232 |
| 12.4.1 Epidemiology . . . . .                              | 232 |
| 12.4.2 Molecular Biology and Genetics . . . . .            | 232 |
| 12.4.3 Diagnostic Criteria and Clinical Features . . . . . | 232 |
| 12.4.4 Natural History and Prognosis . . . . .             | 233 |
| 12.4.5 Laboratory Studies . . . . .                        | 233 |
| 12.4.6 Imaging Studies . . . . .                           | 234 |
| 12.4.7 Treatment . . . . .                                 | 235 |
| <b>12.5 Ataxia-Telangiectasia</b> . . . . .                | 235 |
| 12.5.1 Epidemiology . . . . .                              | 235 |
| 12.5.2 Molecular Biology and Genetics . . . . .            | 235 |
| 12.5.3 Diagnostic Criteria & Clinical Features . . . . .   | 236 |
| 12.5.4 Natural History and Prognosis . . . . .             | 236 |
| 12.5.5 Laboratory Studies . . . . .                        | 237 |
| 12.5.6 Imaging Studies . . . . .                           | 237 |
| 12.5.7 Treatment . . . . .                                 | 237 |
| <b>12.6 Von-Hippel Lindau Syndrome</b> . . . . .           | 237 |
| 12.6.1 Epidemiology . . . . .                              | 237 |

|                                                            |     |
|------------------------------------------------------------|-----|
| 12.6.2 Molecular Biology and Cytogenetics . . . . .        | 238 |
| 12.6.3 Diagnostic Criteria and Clinical Features . . . . . | 238 |
| 12.6.4 Natural History and Prognosis . . . . .             | 239 |
| 12.6.5 Laboratory Studies . . . . .                        | 239 |
| 12.6.6 Imaging Studies . . . . .                           | 239 |
| 12.6.7 Treatment . . . . .                                 | 240 |
| <b>12.7 Sturge-Weber Syndrome</b> . . . . .                | 240 |
| 12.7.1 Epidemiology . . . . .                              | 240 |
| 12.7.2 Genetic and Molecular Biology . . . . .             | 240 |
| 12.7.3 Diagnostic Criteria and Clinical Features . . . . . | 240 |
| 12.7.4 Natural History and Prognosis . . . . .             | 241 |
| 12.7.5 Laboratory Studies . . . . .                        | 242 |
| 12.7.6 Imaging Studies . . . . .                           | 242 |
| 12.7.7 Treatment . . . . .                                 | 242 |
| <b>12.8 Conclusions</b> . . . . .                          | 242 |
| <b>References</b> . . . . .                                | 243 |

## **13 Modern Neuroimaging of Pediatric Brain Tumors**

Sean O. Bryant • Soonmee Cha •  
A. James Barkovich

|                                                                   |     |
|-------------------------------------------------------------------|-----|
| <b>13.1 Modern Neuroimaging of Pediatric CNS Tumors</b> . . . . . | 247 |
| <b>13.2 MR Spectroscopy</b> . . . . .                             | 247 |
| 13.2.1 Principles . . . . .                                       | 247 |
| 13.2.2 Technique . . . . .                                        | 248 |
| 13.2.3 Application . . . . .                                      | 248 |
| <b>13.3 MR Perfusion</b> . . . . .                                | 250 |
| 13.3.1 Principles . . . . .                                       | 250 |
| 13.3.2 Technique . . . . .                                        | 252 |
| 13.3.3 Applications . . . . .                                     | 253 |
| 13.3.4 Limitations . . . . .                                      | 256 |
| <b>13.4 Nuclear Medicine</b> . . . . .                            | 256 |
| 13.4.1 Principles . . . . .                                       | 256 |
| 13.4.2 Mechanism and Technique . . . . .                          | 256 |
| 13.4.3 Applications and Limitations . . . . .                     | 257 |
| <b>13.5 BOLD/MSI</b> . . . . .                                    | 259 |
| 13.5.1 Principles . . . . .                                       | 259 |
| 13.5.2 Mechanism of BOLD Imaging . . . . .                        | 259 |
| 13.5.3 Mechanism of MSI . . . . .                                 | 259 |
| 13.5.4 Applications of BOLD and MSI . . . . .                     | 260 |
| 13.5.5 Limitations . . . . .                                      | 261 |
| <b>13.6 Diffusion Imaging</b> . . . . .                           | 261 |
| 13.6.1 Principles . . . . .                                       | 261 |
| 13.6.2 Technique . . . . .                                        | 261 |
| 13.6.3 Applications . . . . .                                     | 262 |

|                                                                           |     |
|---------------------------------------------------------------------------|-----|
| <b>13.7 Magnetization Transfer</b> . . . . .                              | 263 |
| 13.7.1 Principles . . . . .                                               | 263 |
| 13.7.2 Technique . . . . .                                                | 264 |
| 13.7.3 Applications . . . . .                                             | 265 |
| <b>13.8 Improving Image Sensitivity to Analyze Small Tumors</b> . . . . . | 265 |
| <b>13.9 Conclusions</b> . . . . .                                         | 266 |
| <b>References</b> . . . . .                                               | 266 |

## **14 Current Surgical Management**

Nalin Gupta • Kurtis I. Auguste •  
Mitchel S. Berger

|                                                                        |     |
|------------------------------------------------------------------------|-----|
| <b>14.1 Introduction</b> . . . . .                                     | 273 |
| <b>14.2 Technical Adjuncts for Resection of Brain Tumors</b> . . . . . | 274 |
| 14.2.1 Ultrasound . . . . .                                            | 274 |
| 14.2.2 Neuronavigation . . . . .                                       | 274 |
| 14.2.3 Functional Imaging . . . . .                                    | 275 |
| 14.2.4 Cortical Mapping for Supratentorial Tumors . . . . .            | 277 |
| 14.2.5 Mapping of Seizure Foci . . . . .                               | 278 |
| <b>14.3 Posterior Fossa Tumors</b> . . . . .                           | 278 |
| 14.3.1 Surgical Principles . . . . .                                   | 278 |
| 14.3.2 Complications . . . . .                                         | 280 |
| <b>14.4 The Role of Second-look Surgery</b> . . . . .                  | 282 |
| <b>14.5 Conclusions</b> . . . . .                                      | 283 |
| <b>References</b> . . . . .                                            | 283 |

## **15 Chemotherapy**

Theodore Nicolaides • Biljana Horn •  
Anuradha Banerjee

|                                                                                  |     |
|----------------------------------------------------------------------------------|-----|
| <b>15.1 Introduction</b> . . . . .                                               | 287 |
| <b>15.2 General Principles of Chemotherapy</b> . . . . .                         | 288 |
| <b>15.3 Specific Chemotherapeutic Agents</b> . . . . .                           | 288 |
| 15.3.1 Platinums . . . . .                                                       | 288 |
| 15.3.2 Nitrosoureas . . . . .                                                    | 289 |
| 15.3.3 Cyclophosphamide and Ifosfamide . . . . .                                 | 289 |
| 15.3.4 Temozolomide . . . . .                                                    | 290 |
| 15.3.5 Etoposide . . . . .                                                       | 290 |
| 15.3.6 Vincristine . . . . .                                                     | 290 |
| 15.3.7 Vinblastine . . . . .                                                     | 291 |
| 15.3.8 Methotrexate . . . . .                                                    | 291 |
| <b>15.4 Combination Chemotherapy for Infant Brain Tumors</b> . . . . .           | 291 |
| <b>15.5 High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue</b> . . . . . | 293 |
| 15.5.1 Rationale . . . . .                                                       | 293 |
| 15.5.2 Medulloblastoma . . . . .                                                 | 293 |

|                                                                       |     |
|-----------------------------------------------------------------------|-----|
| 15.5.3 Gliomas . . . . .                                              | 295 |
| 15.5.4 Other Tumor Types . . . . .                                    | 296 |
| <b>15.6 New Strategies</b> . . . . .                                  | 297 |
| 15.6.1 Radiation Sensitizers . . . . .                                | 297 |
| 15.6.2 Targeting Drug Resistance . . . . .                            | 297 |
| 15.6.3 Molecular Targets and Signal Transduction Inhibition . . . . . | 298 |
| 15.6.4 Angiogenesis Inhibitors . . . . .                              | 298 |
| 15.6.5 Overcoming the Blood-Brain Barrier . . . . .                   | 299 |
| 15.6.6 Differentiation of Neoplastic Cells . . . . .                  | 301 |
| 15.6.7 Gene Therapy . . . . .                                         | 301 |
| 15.6.8 Immunotherapy . . . . .                                        | 302 |
| <b>15.7 Conclusions</b> . . . . .                                     | 303 |
| <b>References</b> . . . . .                                           | 304 |

## **16 Advances in Radiation Therapy**

Sean M. McBride • Daphne A. Haas-Kogan

|                                                                     |     |
|---------------------------------------------------------------------|-----|
| <b>16.1 Introduction</b> . . . . .                                  | 313 |
| <b>16.2 Radiobiology</b> . . . . .                                  | 313 |
| <b>16.3 Three-Dimensional Conformal Radiation Therapy</b> . . . . . | 314 |
| 16.3.1 Immobilization and Imaging . . . . .                         | 314 |
| 16.3.2 Target Definition and Planning . . . . .                     | 315 |
| 16.3.3 Treatment Verification and Delivery . . . . .                | 316 |
| <b>16.4 New Technical Approaches</b> . . . . .                      | 317 |
| 16.4.1 Intensity Modulated Radiation Therapy . . . . .              | 317 |
| 16.4.2 Proton Beam Therapy . . . . .                                | 320 |
| 16.4.3 Intraoperative Radiotherapy . . . . .                        | 320 |
| 16.4.4 Temporary or Permanent Brachytherapy . . . . .               | 321 |
| 16.4.5 Stereotactic Radiosurgery and Radiotherapy . . . . .         | 321 |
| 16.4.6 Neutron Beam Therapy . . . . .                               | 322 |
| 16.4.7 Boron Neutron Capture Therapy . . . . .                      | 322 |
| <b>16.5 Toxicity of Radiation Therapy</b> . . . . .                 | 322 |
| 16.5.1 Spinal Cord . . . . .                                        | 323 |
| 16.5.2 Brain . . . . .                                              | 323 |
| 16.5.3 Eye . . . . .                                                | 325 |
| 16.5.4 Ear . . . . .                                                | 325 |
| 16.5.5 Endocrine . . . . .                                          | 325 |
| <b>16.6 Molecular Targets for Radiosensitization</b> . . . . .      | 326 |
| 16.6.1 Tyrosine Kinase Receptors . . . . .                          | 326 |
| 16.6.2 Molecular Targeting and Radiosensitization . . . . .         | 328 |
| 16.6.3 P53 Tumor Suppressor Protein . . . . .                       | 329 |
| <b>16.7 Conclusions</b> . . . . .                                   | 329 |
| <b>References</b> . . . . .                                         | 330 |

## 17 Late Effects of Treatment and Palliative Care

Denah Taggart • Robert Goldsby •  
Anuradha Banerjee

|             |                      |     |
|-------------|----------------------|-----|
| <b>17.1</b> | <b>Introduction</b>  | 335 |
| <b>17.2</b> | <b>Late Effects</b>  | 335 |
| 17.2.1      | Mortality            | 336 |
| 17.2.2      | Secondary Malignancy | 336 |
| 17.2.3      | General Late Effects | 337 |
| 17.2.4      | Neurologic           | 337 |
| 17.2.5      | Neurocognitive       | 339 |
| 17.2.6      | Neuropsychology      | 339 |
| 17.2.7      | Psychosocial         | 340 |
| 17.2.8      | Endocrine            | 340 |
| 17.2.9      | Other                | 341 |

|                   |                                                                  |     |
|-------------------|------------------------------------------------------------------|-----|
| 17.2.10           | Patient Factors                                                  | 341 |
| 17.2.11           | Treatment Factors                                                | 342 |
| 17.2.12           | Recommendations for<br>Late Effects Care                         | 342 |
| <b>17.3</b>       | <b>Palliative Care</b>                                           | 343 |
| 17.3.1            | Developmental Stage                                              | 345 |
| 17.3.2            | Communication                                                    | 346 |
| 17.3.3            | Team Approach                                                    | 347 |
| 17.3.4            | Pain and Symptom Management                                      | 347 |
| <b>17.4</b>       | <b>Ethical Considerations<br/>of Clinical Trials and Consent</b> | 350 |
| <b>17.5</b>       | <b>Bereavement</b>                                               | 350 |
| <b>References</b> |                                                                  | 350 |

|                      |     |
|----------------------|-----|
| <b>Subject Index</b> | 355 |
|----------------------|-----|